Non-selective CB1R/CB2R agonists on the other hand, including Δ9-THC, CBD, and various Cannabis sativa extracts, revealed mixed results for Δ9-THC but consistent positive outcomes for CBD in reversing AD traits through PPAR-γ receptor activation. Here, CNR1 is linked to Alzheimer disease.